178 related articles for article (PubMed ID: 15106619)
1. Beta-adrenoceptor polymorphisms and heart failure.
Lohse MJ
Trends Mol Med; 2004 Feb; 10(2):55-8. PubMed ID: 15106619
[TBL] [Abstract][Full Text] [Related]
2. Adrenergic receptor polymorphisms in heart failure: what can genetics explain?
Pereira SB; Gava IA; Giro C; Mesquita ET
Arq Bras Cardiol; 2010 Jun; 94(6):841-9. PubMed ID: 20625643
[TBL] [Abstract][Full Text] [Related]
3. Adrenergic receptor polymorphisms and prevention of ventricular arrhythmias with bucindolol in patients with chronic heart failure.
Aleong RG; Sauer WH; Robertson AD; Liggett SB; Bristow MR
Circ Arrhythm Electrophysiol; 2013 Feb; 6(1):137-43. PubMed ID: 23275278
[TBL] [Abstract][Full Text] [Related]
4. Heterozygous alpha 2C-adrenoceptor-deficient mice develop heart failure after transverse aortic constriction.
Gilsbach R; Brede M; Beetz N; Moura E; Muthig V; Gerstner C; Barreto F; Neubauer S; Vieira-Coelho MA; Hein L
Cardiovasc Res; 2007 Sep; 75(4):728-37. PubMed ID: 17597596
[TBL] [Abstract][Full Text] [Related]
5. Alteration of the beta-adrenergic signaling pathway in human heart failure.
Hamdani N; Linke WA
Curr Pharm Biotechnol; 2012 Oct; 13(13):2522-31. PubMed ID: 22280427
[TBL] [Abstract][Full Text] [Related]
6. Synergistic polymorphisms of beta1 and alpha2C-adrenergic receptors and the influence on left ventricular ejection fraction response to beta-blocker therapy in heart failure.
Lobmeyer MT; Gong Y; Terra SG; Beitelshees AL; Langaee TY; Pauly DF; Schofield RS; Hamilton KK; Herbert Patterson J; Adams KF; Hill JA; Aranda JM; Johnson JA
Pharmacogenet Genomics; 2007 Apr; 17(4):277-82. PubMed ID: 17496726
[TBL] [Abstract][Full Text] [Related]
7. Tight control of adrenal medulla catecholamine release by alpha 2C-adrenergic receptors influences susceptibility to heart failure.
Petrashevskaya N; Liggett SB
Cardiovasc Res; 2007 Sep; 75(4):631-3. PubMed ID: 17643402
[No Abstract] [Full Text] [Related]
8. Polymorphisms of adrenoceptors are not associated with an increased risk of adverse event in heart failure: a MERIT-HF substudy.
Savva J; Maqbool A; White HL; Galloway SL; Yuldasheva NY; Ball SG; West RM; De Boer RA; Van Veldhuisen DJ; Balmforth AJ;
J Card Fail; 2009 Jun; 15(5):435-41. PubMed ID: 19477404
[TBL] [Abstract][Full Text] [Related]
9. An alpha2C-adrenergic receptor polymorphism alters the norepinephrine-lowering effects and therapeutic response of the beta-blocker bucindolol in chronic heart failure.
Bristow MR; Murphy GA; Krause-Steinrauf H; Anderson JL; Carlquist JF; Thaneemit-Chen S; Krishnan V; Abraham WT; Lowes BD; Port JD; Davis GW; Lazzeroni LC; Robertson AD; Lavori PW; Liggett SB
Circ Heart Fail; 2010 Jan; 3(1):21-8. PubMed ID: 19880803
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic implications of beta-adrenergic receptor pharmacodynamic properties.
Taira CA; Carranza A; Mayer M; Di Verniero C; Opezzo JA; Höcht C
Curr Clin Pharmacol; 2008 Sep; 3(3):174-84. PubMed ID: 18781904
[TBL] [Abstract][Full Text] [Related]
11. Polymorphisms of adrenergic receptors and the risk of heart failure.
Meisel C; Köpke K; Roots I
N Engl J Med; 2003 Jan; 348(5):468-70; author reply 468-70. PubMed ID: 12556550
[No Abstract] [Full Text] [Related]
12. Lack of association between adrenergic receptor genotypes and survival in heart failure patients treated with carvedilol or metoprolol.
Sehnert AJ; Daniels SE; Elashoff M; Wingrove JA; Burrow CR; Horne B; Muhlestein JB; Donahue M; Liggett SB; Anderson JL; Kraus WE
J Am Coll Cardiol; 2008 Aug; 52(8):644-51. PubMed ID: 18702968
[TBL] [Abstract][Full Text] [Related]
13. Polymorphisms determine beta-adrenoceptor conformation: implications for cardiovascular disease and therapy.
Ahles A; Engelhardt S
Trends Pharmacol Sci; 2009 Apr; 30(4):188-93. PubMed ID: 19272658
[TBL] [Abstract][Full Text] [Related]
14. Beta-adrenoceptor polymorphisms.
Leineweber K; Büscher R; Bruck H; Brodde OE
Naunyn Schmiedebergs Arch Pharmacol; 2004 Jan; 369(1):1-22. PubMed ID: 14647973
[TBL] [Abstract][Full Text] [Related]
15. [Importance of beta 2-adrenergic receptors in heart failure].
Brodde OE; Daul A; Michel MC; Zerkowski HR
Z Kardiol; 1992; 81 Suppl 4():71-8. PubMed ID: 1363262
[TBL] [Abstract][Full Text] [Related]
16. Combinatorial pharmacogenetic interactions of bucindolol and β1, α2C adrenergic receptor polymorphisms.
O'Connor CM; Fiuzat M; Carson PE; Anand IS; Plehn JF; Gottlieb SS; Silver MA; Lindenfeld J; Miller AB; White M; Walsh R; Nelson P; Medway A; Davis G; Robertson AD; Port JD; Carr J; Murphy GA; Lazzeroni LC; Abraham WT; Liggett SB; Bristow MR
PLoS One; 2012; 7(10):e44324. PubMed ID: 23071495
[TBL] [Abstract][Full Text] [Related]
17. The pharmacogenetics of β-adrenergic receptor antagonists in the treatment of hypertension and heart failure.
Chan SW; Hu M; Tomlinson B
Expert Opin Drug Metab Toxicol; 2012 Jul; 8(7):767-90. PubMed ID: 22621216
[TBL] [Abstract][Full Text] [Related]
18. The beta-adrenergic pathway in the failing human heart: implications for inotropic therapy.
Feldman AM; Bristow MR
Cardiology; 1990; 77 Suppl 1():1-32. PubMed ID: 1970755
[No Abstract] [Full Text] [Related]
19. β1- and α2C-adrenergic receptor polymorphisms and the antiarrhythmic effect of bucindolol in heart failure with reduced ejection fraction.
Lymperopoulos A; Negussie S; Walklett K
Pharmacogenomics; 2013 Oct; 14(13):1545-9. PubMed ID: 24088125
[No Abstract] [Full Text] [Related]
20. β-Adrenergic Receptor Signaling and Heart Failure: From Bench to Bedside.
Bencivenga L; Liccardo D; Napolitano C; Visaggi L; Rengo G; Leosco D
Heart Fail Clin; 2019 Jul; 15(3):409-419. PubMed ID: 31079699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
